In this section
Coronavirus and MS services
Disease modifying Treatments
If you are on an injectable treatment: Glatiramer acetate (Brabio/Copaxone), Interferon beta 1a (Avonex, Plegridy, Rebif), Interferon 1b (Betaferon), or an oral treatment such as Dimethyl fumarate (Tecfidera), Fingolimod (Gilenya) and Teriflunomide (Aubagio) your treatment will not be altered, unless your blood test results indicate that you may be at higher risk of infection. The MS nurse team will contact you directly if this applies to you.
If you are on Natalizumab (Tysabri) infusions, your infusions will continue.
If you have already been treated with Alemtuzumab (Lemtrada), Ocrelizumab (Ocrevus) and Cladribine (Mavenclad) your care will continue as before. The MS team will be in contact if you are due a repeat treatment soon.
If you are waiting to start a treatment such as Alemtuzumab (Lemtrada), Ocrelizumab (Ocrevus) and Cladribine (Mavenclad), the MS Team will also be in contact with you to discuss this.
Appointments and Covid-19
Appointments for physiotherapy are currently being managed by virtual/ telephone. If you are on the physiotherapy waiting list you will be contacted by a member of the team to assess your needs. At present the physiotherapy service are not able to offer block bookings for appointments due to capacity.
The MS nursing team will continue to offer telephone clinic appointments but will be able to offer some face to face reviews and incorporating virtual appointments.